Search results
We review clinical development of remdesivir, a prodrug with a demonstrated ability to inhibit SARS-CoV-2 replication, which supports its clinical evaluation for COVID-19 treatment.
Subsequent evaluation by numerous virology laboratories demonstrated the ability of remdesivir to inhibit coronavirus replication, including SARS-CoV-2. Here, we provide an overview of remdesivir’s discovery, mechanism of action, and the current studies exploring its clinical effectiveness.
23 lip 2021 · Given the time-consuming process of drug development, repurposing drugs approved for other indications or at least successfully tested in terms of safety and tolerability, is an attractive strategy to rapidly provide an effective medication for severe COVID-19 cases.
27 sie 2021 · Remdesivir (RDV), formerly known as GS-5734, is a 1-cyano-substituted adenine C-nucleoside ribose analog that inhibits the RdRp of many viruses. In human macrophages, RDV exposure causes an accumulation of the drug, which is then rapidly converted into its active triphosphate metabolite.
1 maj 2020 · This article summarizes the milestones in the development of remdesivir leading to its first conditional approval for the treatment of COVID-19.
28 wrz 2021 · Great efforts have been put into the development of novel drugs against SARS-CoV-2 infection. Currently, remdesivir (RDV) (Fig. 1a), an intravenously administered nucleotide prodrug, is...
11 cze 2021 · Between various antiviral candidate therapies, remdesivir has demonstrated to be a potent antiviral drug that inhibits viral RNA synthesis. Recently, there are supportive evidences for yielding some clinical improvement in COVID-19 patients.
